Trending Topic

roflilumast foam
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The FDA recently approved roflumilast 0.3% foam for the treatment of plaque psoriasis of the scalp and body in both adolescents and adults. To better understand how this newly approved therapy fits into clinical practice, what the data show and which patients are likely to benefit, we spoke with Dr Jennifer Soung (Harbor University of California, Los Angeles and Southern California Dermatology, Santa Ana, CA, USA), a key investigator on the phase 3 ARRECTOR trial.

Medics4RareDiseases

Medics4RareDiseases
Web Address: Medics4RareDiseases

Medics4RareDiseases (or M4RD) is UK charity with a mission to build a healthcare workforce that is trained and supported to meet the needs of those living with rare conditions, so that patients feel listened to, believed and involved. The charity has a vision for a world in which no one faces inequality in healthcare based on the rarity of their condition.

M4RD works closely with patients and rare disease advocates, and alongside universities, foundation schools, royal colleges, hospitals and trusts. The charity creates patient-centred, dedicated rare disease education for healthcare professionals. This can be provided in-person or accessed online at https://learn.m4rd.org. M4RD also works with governmental bodies and outside organisations to advocate for the inclusion of dedicated Rare Disease training within the medical education curricula.

M4RD started out as a medical student society Barts and The London School of Medicine and Dentistry, QMUL in 2011. It was registered as a charity in 2018 and made major contributions to the development of The UK Rare Diseases Framework published by the Department of Health and Social Care. M4RD continues to advise on implementation and development of policy for rare disease.

Further Resources

Close Popup